• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

7.425 -0.515 (-6.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ARS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
ARS Pharma (SPRY) Q4 2025 Earnings Transcript ↗
Today 17:58 EDT
ARS Pharma (SPRY) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
ARS Pharmaceuticals Q1 Earnings Call Highlights ↗
Today 12:09 EDT
ARS Pharmaceuticals (NASDAQ:SPRY) reported first-quarter 2026 revenue of $22.7 million as executives said the company is working to expand access, reduce prescribing friction and build momentum for... 
Via MarketBeat
Topics Earnings
ARS Pharmaceuticals (NASDAQ:SPRY) Reports Revenue Growth in Q1 2026, Net Loss Widens on Commercial Investment ↗
Today 7:20 EDT
Via Chartmill
News headline image
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
Today 6:00 EDT
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 10, 2025 ↗
November 10, 2025
 
Via Benzinga
News headline image
Earnings Outlook For ARS Pharmaceuticals ↗
November 07, 2025
 
Via Benzinga
News headline image
ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗
Today 2:08 EDT
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) to release first quarter earnings on May 15 before opening bell. Analysts expect a loss of 54 cents per share. 
Via Benzinga
News headline image
ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President
May 13, 2026
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
May 07, 2026
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
April 15, 2026
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
March 27, 2026
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization
March 09, 2026
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences
February 23, 2026
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Got $300? 2 Biotech Stocks to Buy and Hold Forever ↗
February 16, 2026
These two biotechs only have one marketable therapy each, but both have blockbuster potential. 
Via The Motley Fool
News headline image
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
February 10, 2026
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
February 02, 2026
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
January 21, 2026
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)
December 29, 2025
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
November 26, 2025
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharma SPRY Q3 2025 Earnings Call Transcript ↗
November 10, 2025
ARS Pharma SPRY Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
ARS Pharmaceuticals Inc (NASDAQ:SPRY) Tops Q3 2025 Revenue Forecasts Amid Wider-Than-Expected Loss ↗
November 10, 2025
ARS Pharma beats Q3 2025 revenue estimates with strong neffy sales. The company reports a wider loss but shows robust commercial growth and global expansion. 
Via Chartmill
News headline image
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
November 10, 2025
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)
November 04, 2025
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
November 03, 2025
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results
November 03, 2025
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
November 03, 2025
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)
October 08, 2025
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
October 03, 2025
 
Via Benzinga
News headline image
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
September 29, 2025
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharma Urges FDA To Delay Approval Of Aquestive's Allergic Reaction Treatment ↗
September 23, 2025
ARS Pharmaceuticals petitioned the FDA to delay approval of Aquestive's epinephrine film, citing safety, dosing, and cardiovascular concerns. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap